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Neurofilaments in blood and CSF 
for diagnosis and prediction of 
onset in Creutzfeldt-Jakob disease
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Patrick Oeckl1, Armin Giese4, Jens Kuhle5, Dana Slivarichova6, Henrik Zetterberg2,3,7,* & 
Markus Otto1,*
While cerebrospinal fluid (CSF) biomarkers for Creutzfeldt-Jakob disease (CJD) are established and 
partly included in the diagnostic criteria, no blood biomarkers are available. Here, we assessed the 
utility of serum neurofilament light chain (NF-L) and tau protein in comparison to CSF markers (NF-L 
and phosphorylated NF heavy chain (pNF-H), tau, S100B, 14-3-3) and prion conversion assay (real-
time quaking induced conversion (RT-QuIC)) for sporadic and genetic CJD. Importantly, a Gerstmann-
Sträussler-Scheinker mutation carrier in the asymptomatic phase and at disease onset was included 
as well. Both NF-L and tau were markedly increased in CJD serum, reaching similar or even better 
performance as in CSF (sensitivity and specificity for serum NF-L 100% and 85.5%, and for serum tau 
84.6% and 96.2%, respectively). Serum S100B showed high sensitivity as well (84.2%), but lower 
specificity (63%). CSF neurofilaments were increased before symptom onset, while prion seeding assay 
was negative. Just before a clinical diagnosis could be made, all CSF markers and NF-L in the serum 
were increased and CSF prion conversion assay was positive. The data suggest that neurofilaments are 
sensitive and specific blood markers for the diagnosis of genetic and sporadic CJD and might represent 
promising tools to predict disease onset.
Prion diseases are transmissible and fatal neurodegenerative diseases neuropathologically characterized by the 
presence of misfolded prion proteins, which are exceptionally resistant to routine decontamination procedures. 
The availability of an easy, early, and reliable test in prion disorders is therefore a relevant issue both for public 
health reasons and for establishing diagnosis, but also for differential diagnosis with other treatable conditions.
The diagnosis of sporadic and genetic CJD can be supported by fluid biomarkers, including 14-3-3 pro-
teins, tau proteins, neurofilaments and S100B in cerebrospinal fluid (CSF)1–6. Potential blood markers comprise 
acute-phase proteins7 and S100B8. Among the mentioned candidate markers, only 14-3-3 in the CSF was included 
into the diagnostic criteria by the WHO.
While for a long time the detection of misfolded prion protein in body fluids failed, some approaches have 
eventually been successful9 and high diagnostic accuracy was reported for the recently developed real-time quak-
ing induced conversion (RT-QuIC) prion conversion assay which uses minute amounts of the β -structure-rich 
insoluble conformer of the prion protein (PrPSc) in CSF as seeds10,11 while other studies report lower diagnostic 
performance12. Further, it is unclear when the misfolded prion protein appears or reaches the detectable limit in 
CSF of CJD patients. However, for disease onset, especially in genetic cases, blood markers are needed with the 
perspective to have an objective read-out for therapeutic trials. Presently, no validated blood biomarker for the 
differential diagnosis and prediction of onset exists.
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In the present study we therefore addressed the questions whether we can measure these biomarkers with 
newly established assays in blood, of which diagnostic value they are, and how early in the disease process these 
markers appear.
Results
A summary of the marker concentrations, cut-off levels, and diagnostic performance in terms of sensitivity and 
specificity as well as the positive and negative predictive values for the discrimination between CJD and controls 
is given in Table 1.
Surrogate marker concentrations in serum. Boxplots of marker levels in serum of the diagnostic 
groups are shown in Fig. 1A–C. NF-L serum concentrations were higher in both sCJD and gCJD compared to 
DCo or Co. At 44.7 pg/ml cut-off 100% sensitivity and 85.5% specificity was reached for discrimination between 
CJD and controls.
Serum tau was significantly different in sCJD, but not gCJD, and controls. At 2.2 pg/ml cut-off, CJD was rec-
ognized with 84.6% sensitivity and 96.2% specificity.
n age (years)a gender (f/m)
serum NF-L 
(pg/ml)b
serum tau 
(pg/ml)b
serum S100 
(pg/ml)b
CSF NF-L  
(pg/ml)b
CSF tau  
(pg/ml)b
CSF pNF-H 
(pg/ml)b
14-3-3 
pos./neg.
RT-QuIC 
pos./neg
Co 40 64 (59–69) 24/16 49.2 ± 81.5 0.8 ± 1.2 68.6 ± 55.4 1632 ± 3328 293 ± 213 398 ± 759 n.d. 0/6 n = 6
DCo 20 64(62–67) 10/10 25.7 ± 25.7 0.6 ± 0.3 66.6 ± 20.5 1502 ± 1234 502 ± 266 331 ± 437 n.d. n.d.
CJD 43 63(58–71) 23/22 296.9 ± 253.0 54.2 ± 90.7 95.8 ± 31.6 8908 ± 7056 2080 ± 530 3602 ± 2393 10/4 n = 14
sporadic 
CJDc 33 63 (58–80) 20/13 317.2 ± 282.3 67 ± 100 97.4 ± 31.4 8087 ± 6469 2152 ± 320 3255 ± 2254 28/5 6/1
d n = 7
24 M/M 63(47–80) 15/9 274.0 ± 182.0 58.4 ± 95.1 101.2 ± 23.0 8242 ± 6817 4696 ± 3893 3252 ± 2048 21/3 4/1 n = 5
3 M/Ve 66(58–79) 3/0 88.8; 1038.7; 1308.4 2.7; 6.0; 275.7 n.d. 5056; 17985 2312; 3693 594; 7740 1/2 n.d.
1 V/Vf 64 m 313.6 4.1 50 32190 4245 8514 pos. pos.
genetic CJD 9 63 (54–73) 3/8 222.8 ± 111.4 11.0 ± 21.5 99.5 ± 31.34 8784 ± 4239 1939 ± 1426 4115 ± 2342 7/3 4/3
E196K 72 m 133.4 5.0 96 17155 3360 8310 pos. neg.
E200K 75 m 234.3 65.9 131 8400 340 6654 pos. neg.
E200K 45 m 72.9 0.1 109 13920 2478 4490 pos. pos.
E200K 72 m 279.8 1.2 52 5957 1657 2460 pos. neg.
insert 
(5 × 24) 63 m 146.1 19.8 n.d. 8265 < 45 n.d. neg. n.d.
insert 
(5 × 24) 73 m 393.8 4.6 140 7043 n.d. 4185 neg. pos.
insert 
(4 × 24) 57 f 115.2 1.1 120 7209 3902 1866 pos. pos.
V210I 77 f 345.3 0.5 83 3056 907 1761 pos. pos.
V210I 54 m 284.3 0.9 65 8050 2824 3192 pos. n.d.
P102L 
presympt. 50
f
63.6 n.d. 74 8146 459 1500 n.d. neg.
P102L 
onset 52 189.1 n.d. 181 20690 1969 4089 neg. pos.
cut-offg > 44.70 > 2.195 > 64.00 > 2156 > 987.5 > 562.5
sensitivityg 100% (69.5–94.1)
84.6% 
(69.5–94.1)
84.2% 
(60.4–96.6)
97.3% 
(85.8–99.9)
88.9% 
(73.9–96.9)
100.0% 
(90–100) n.a.
71.4% 
(41.9–91.6)
specificityg 85.5% (86.8–99.5)
96.2% 
(73.3–93.5)
63.2% 
(46–78.2)
86.5% 
(74.2–94.4)
98.1% 
(89.7–100)
88.5% 
(76.6–95.7) n.a.
100% 
(55.1–100)
PPVg 0.837  (0.698–0.922)
0.920  
(0.764–0.926)
0.790  
(0.539–0.930)
0.818  
(0.668–0.913)
0.970  
(0.825–0.998)
0.854  
(0.701–0.939) n.a. 1 (0.656–1)
NPVg 0.979  (0.875–0.999)
0.853  
(0.733–0.927)
0.6  
(0.274–0.863)
0.978  
(0.868–0.999)
0.927  
(0.816–0.976) 1 (0.904–1) n.a.
0.6  
(0.274–0.863)
Table 1.  Demographic characteristics of the patient cohort, marker concentrations in serum and CSF, 
and diagnostic performance. Co, non-demented control; DCo, demented control; f, female; m, male; pos., 
positive; neg., negative; n.d., not determined; n.a., not applicable; PPV, positive predictive value; NPV. negative 
predictive value. aThe age is given as median with interquartile range. bThe markers are given as mean with 
standard deviation. cCodon 129 polymorphism was determined for 28 sporadic CJD cases. dFor 5 out of 7 CJD 
analyzed for CSF prion seeding activity the codon 129 polymorphism was known. eFor the patients with M/V 
individual marker concentrations are given; CSF parameters missing for one patient. fThis patient also had an 
A117A polymorphism. gCalculated for discrimination between all CJD versus all control measures; given with 
95% confidence intervals in brackets.
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The concentrations determined for S100B in serum samples differed significantly between all CJD and DCo 
(p = 0.0006), but post hoc test after Kruskal-Wallis test (p = 0.0465) revealed no significant differences between 
sCJD, gCJD, and DCo (Fig. 1C).
At the presymptomatic stage serum tau and S100B were similar to control levels, whereas NF-L tended to 
be elevated, and at symptom onset serum markers were clearly increased (green and red circles respectively in 
Fig. 1A–C).
ROC analysis of serum marker concentrations of all CJD versus all controls yielded comparable estimates for 
the AUC for NF-L and tau (Fig. 1G).
Surrogate marker concentrations in CSF. Boxplots of the marker levels in CSF samples of the diagnostic 
groups are shown in Fig. 1D–F.
The levels of NF-L and pNF-H in CSF samples were strongly increased in CJD compared to both control 
groups. CSF tau concentrations were significantly increased in CJD as well, however, due to low levels in an 
E200K and the insert 4 × 24 carrier, the difference between gCJD and DCo was not significant.
Figure 1. Marker concentrations, ROC diagrams, and RT-QuIC results for CJD and controls. Boxplots 
show the serum levels of NF-L (A), tau (B), and S100B (C), as well as the CSF levels of NF-L (D), tau (E), and 
pNF-H (F). Displayed are the results for CJD patients (indicated separately for sCJD and gCJD) and from 
demented (DCo) and non-demented controls (Co). The concentrations of analytes determined in serum and 
CSF from a gCJD patient at presymptomatic and early symptomatic disease stage are indicated by green and red 
circles, respectively. Boxes give median values with interquartile ranges, whiskers indicate the concentration 
range. Three and two asterisks indicate statistically significant differences of p < 0.0001 and p < 0.01, 
respectively. The diagnostic performance of markers is illustrated by ROC curves for serum (G) and CSF (H). 
Except for S100B, of which levels were determined in DCo only, ROC analyses were conducted considering all 
CJD measures (i.e. sCJD and gCJD) versus all controls (i.e. DCo and Co). The results of RT-QuIC are shown 
in (I). Displayed are the mean fluorescence signals with SD detected in the CSF of sCJD patients (n = 6), gCJD 
patients (n = 4), and controls (n = 6). Separately shown are the results for 3 replicate measurements of the gCJD 
mutation carrier in the asymptomatic disease stage (orange) and at disease onset (red).
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At the presymptomatic disease stage, CSF tau was normal and NF-L and especially pNF-H were already 
elevated above the 75% quartile of controls. At disease onset all CSF markers were increased. See green and red 
circles in Fig. 1D–F, respectively.
In the ROC analyses pNF-H, tau, and NF-L showed similar performance (Fig. 1H).
Prion seeding activity in CSF. A summary of RT-QuIC results is shown in Fig. 1I. In 10/14 CJD CSF sam-
ples the RT-QuIC assay was positive (71.4% sensitivity). False negative results were obtained for one sample from 
a patient with M/M codon 129 polymorphism and an NF-L serum just above the cut-off level, and for 3 gCJD 
samples from patients with E200 K and E196 K mutations. These 3 patients were positive for CSF 14-3-3 and 
above the cut-off for all other markers, with the exception that the E200 K mutation carrier had a tau CSF level 
clearly below the diagnostic threshold. CSF samples from 6 non demented control cases failed in the RT-QuIC 
assay (100% specificity). After a prolonged amplification time, in 2 out of 6 control CSF samples a signal emerged 
after 48 h and 96 h, respectively, resulting in a signal less than 10% of the signal obtained with CJD samples after 5 
days of measurements. In the CSF from the presymptomatic gCJD patient no seeding activity could be detected. 
At the onset of first symptoms the signal was positive with minimally delayed starting point of about 3 h and a 
maximum similar to that determined in the other positive CJD samples.
Discussion
Today, improvement of CJD diagnosis is attempted in two ways: (1) There is a search for surrogate markers in the 
serum of CJD patients, and (2) Methods are developed to amplify the minute amounts of abnormal PrP present 
in body fluids for a specific diagnosis.
In the present study we show that the known biomarkers NF-L and tau measured in serum samples par-
allel the increase found in CSF, yielding similar statistical significance for differentiation. NF-L, which also is 
elevated in motor neuron disease13–15, is found at even higher levels in CJD patients. pNF-H which was found to 
be increased also in amyotrophic laterla sclerosis (ALS) plasma by in house assays16,17, yielded excellent diagnostic 
performance in CSF in our cohort. Additionally, the analysis of the serum from a presymptomatic gCJD patient 
provides first evidence for pNF-H to be elevated already before symptoms appear and clinical diagnosis can be made.
If serum NF-L qualifies as marker for broad differential diagnoses has to be examined in future studies includ-
ing especially patients with rapidly progressive neurodegenerative dementia. As recent data point to a generally 
strong correlation between CSF and blood levels of NF-L and proteopathic lesions18, high diagnostic power for 
the discrimination of CJD and at least neurodegenerative diseases is likely to be expected.
Serum tau can now be detected more sensitively and is shown for the first time to be increased not only in 
sCJD19 but also in gCJD. Differences between gCJD and controls, however, were less marked compared to NF-L 
and pNF-H.
The time point at which the biomarkers increase in CSF and also in serum is a mostly open question. It can 
be hypothesized that the analyzed markers are increased early in CJD as they indicate neuroaxonal degeneration. 
We found the presymptomatic stage of one CJD mutation carrier characterized by normal serum and CSF tau 
and serum S100B. Neurofilaments, especially pNF-H in the CSF, already show a trend for increased levels and 
might therefore represent candidate markers for the onset of the disease as it was shown for asymptomatic ALS 
gene carrier15. At symptom onset of the gCJD patient, all markers are clearly increased in serum and CSF to the 
range of the CJD cohort.
Similar results were obtained with the specific approach, the RT-QuIC, which has been established for CJD 
diagnostics from CSF12,20,21 and urine22, however, failed to be successful in serum until now. Seeding activity 
could not be detected in the CSF from the presymptomatic phase, but in parallel to the appearance of first CJD 
symptoms.
Taken together, we show that serum NF-L and serum tau can be used in the diagnosis of both sCJD and gCJD 
and provide preliminary evidence that neurofilament levels tend to be increased presymptomatically.
Methods
Patients. This study was conducted according to the principles expressed in the Declaration of Helsinki. 
Collection and analysis of samples were approved by the Ethics Committees of the Medical Faculties of the 
University Göttingen (approval number 100305) and Ulm (approval number 20/10). All patients or their next 
relatives in case of severe dementia gave written informed consent to their participation in the study.
In total, our retrospective study included 103 patients that were seen in the general outpatient clinic and the 
outpatient memory clinic of the Department of Neurology in Ulm and the surveillance unit for transmissible 
spongiform encephalopathies in the Department of Neurology in Göttingen.
All methods were performed in accordance with the relevant guidelines and regulations.
CSF was obtained by lumbar puncture, centrifuged, aliquoted and stored within 2–48 h at − 80 °C until analy-
sis. Serum was processed likewise and stored within 2 h at − 80 °C.
Serum and CSF samples of 43 CJD patients were analyzed, of which 4 had clinically diagnosed “probable CJD” 
(neuropathology missing) and 39 were neuropathologically verified, including 33 sporadic CJD (sCJD) and 9 
genetic CJD (gCJD: E200 K (n = 3), V210I (n = 2), E196 K, insert 5 × 24 (n = 3), and insert 4 × 24). Additionally, 
samples from a 50 year old GSS patient (P102L) at the presymptomatic disease stage and two years later at onset 
of symptoms before clinical diagnosis were included. Control groups comprised 40 patients without signs of 
dementia (Co), and 20 demented patients (DCo) (Alzheimer’s disease n = 12, mild cognitive impairment n = 4, 
frontotemporal dementia n = 3, normal pressure hydrocephalus n = 1).
For demographic characteristics of the diagnostic groups see Table 1.
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Laboratory markers. Serum NF-L and serum tau protein were measured with ultrasensitive Single mole-
cule array (Simoa) assays23–25.
Samples were analyzed for S100B with electrochemiluminescence immunoassay (Elecsys S100B, Roche, 
Penzberg, Germany)8, and with ELISAs for NF-L (IBL, Hamburg, Germany), pNF-H (Biovendor, Heidelberg, 
Germany), and Tau (Fujirebio, Hanover, Germany) according to manufacturer’s specifications. Mean inter-assay 
CV for the ELISAs was < 20%14.
Real-time quaking-induced conversion (RT-QuIC) was carried out as described elsewhere21.
Statistics. Statistical analyses were performed using graphpad prism 5 software. Standard measures of diag-
nostic test validity such as sensitivity, specificity, and predictive values accompanied by their 95% confidence 
intervals (CI) were calculated for varying biomarker cut-off levels. The optimal cut-off level for dichotomizing 
values was selected as the situation maximizing the Youden index26. The receiver operating characteristics (ROC) 
curve is used for a graphical visualization of the impact of the variation in the cut-off values. Two-tailed unpaired 
Mann-Whitney t-test and Kruskal-Wallis test at a significance level of 5% were used to determine statistical dif-
ferences between two groups or more groups, respectively. Dunn’s post hoc comparison was applied following 
Kruskal-Wallis test in case of significant differences.
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